LC
PCRX icon

Lindbrook Capital’s Pacira BioSciences PCRX Stock Holding History

Lindbrook Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$13.1K Sell
527
-4
-0.8% -$96 ﹤0.01% 1540
2024
Q4 		$10K Buy
531
+413
+350% +$7.25K ﹤0.01% 1648
2024
Q3 		$1.78K Sell
118
-56
-32% -$957 ﹤0.01% 2385
2024
Q2 		$4.98K Buy
174
+30
+21% +$854 ﹤0.01% 1994
2024
Q1 		$4.21K Hold
144
– – ﹤0.01% 1968
2023
Q4 		$4.86K Buy
144
+124
+620% +$3.63K ﹤0.01% 1906
2023
Q3 		$614 Buy
+20
New +$721 ﹤0.01% 2494
2023
Q2 		– Sell
-76
Closed -$3.1K – 2823
2023
Q1 		$3.1K Buy
+76
New +$3.02K ﹤0.01% 2059
2022
Q4 		– Sell
-15
Closed -$1K – 2965
2022
Q3 		$1K Buy
15
+7
+88% +$389 ﹤0.01% 2445
2022
Q2 		$0 Buy
+8
New +$524 ﹤0.01% 2694

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Lindbrook Capital's PCRX Position: Q1 2025 in Review

Lindbrook Capital reduced its Pacira BioSciences (PCRX) stake by 0.75% in Q1 2025, selling an estimated $96 and leaving 527 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

Lindbrook Capital first reported a position in PCRX in Q2 2022 and has held it in 10 quarters since. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Lindbrook Capital held 527 shares of Pacira BioSciences worth $13.1K as of Q1 2025.
  • Lindbrook Capital sold 4 Pacira BioSciences shares in Q1 2025, an estimated $96.
  • Pacira BioSciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1540 holding.
  • Lindbrook Capital first reported a position in Pacira BioSciences in Q2 2022 and has held it in 10 quarters since.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.